Nebivolol NDC 59651-137

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-137Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0137Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-137-30	59651013730	30 TABLET in 1 BOTTLE (59651-137-30)Marketed from Feb 19, 2025
59651-137-90	59651013790	90 TABLET in 1 BOTTLE (59651-137-90)Marketed from Feb 19, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Nebivolol
Generic name (nonproprietary): nebivolol
Active ingredients: Nebivolol hydrochloride — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211053
Marketing start: Dec 17, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic beta-Antagonists (Mechanism)
Identifiers: Product ID 59651-137_2690da17-6194-47ba-9078-e27821283ee2SPL ID 2690da17-6194-47ba-9078-e27821283ee2SPL set ID 6e43a4e2-574e-4f4a-804d-e346b4edd2f1RxCUI 387013, 751612, 751618, 827073UNII JGS34J7L9IUPC 0359651137307
Pharmacologic class: beta-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651013730 followed by a unit qualifier and the quantity

Package 59651-0137-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 16, 2026.

Indications (excerpt from the label)

Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies (14.1) ] . Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions (7) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211053

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211053
Product	Strength	Form · route	Labeler	Product NDC
Nebivolol	Nebivolol hydrochloride 20 mg/1	TabletOral	Aurobindo Pharma Limited	59651-140
Nebivolol	Nebivolol hydrochloride 5 mg/1	TabletOral	Aurobindo Pharma Limited	59651-138
Nebivolol	Nebivolol hydrochloride 10 mg/1	TabletOral	Aurobindo Pharma Limited	59651-139
Nebivolol	Nebivolol hydrochloride 20 mg/1	TabletOral	Bryant Ranch Prepack	63629-9423
Nebivolol	Nebivolol hydrochloride 10 mg/1	TabletOral	Bryant Ranch Prepack	63629-9424